Robert J. Harman, D.V.M., M.P.V.M. – Co-Founder, Chief Executive Officer, Chief Scientific Officer
Dr. Harman has more than 22 years of experience as a chief executive officer and biotechnology entrepreneur in four novel businesses, all financial successes. Dr. Harman is a veterinarian and statistician and has overseen the completion of more than 1,000 contract research projects in his career for the development of veterinary and human biotechnology products. He has led the following companies: HTI Bio-Services, a contract research company; HTI Bio-Products, a biological reagent and antibody production company; and Animal Health Ventures, a veterinary product licensing company.
Anne S. Hale, DVM – Chief Development Officer
Dr. Hale has over 30 years of experience in clinical veterinary medicine with an emphasis on translational biopharmaceutical product development and regulatory affairs. As an entrepreneur, a patent holder for point of care testing, and a preclinical trial designer, she is concentrated on bridging veterinary and human medicine to rapidly bring FDA-approved products to patients.
Christopher Rogers, MD – Medical Director
Dr. Christopher Rogers is the founder of the San Diego Orthobiologics Medical Group, a medical practice dedicated to evidence-based musculoskeletal care. He is double-board certified in Physical Medicine & Rehabilitation (PM&R) and Regenerative Medicine. He is fellowship-trained in Interventional Orthopedics and Spine Care and certified in Diagnostic Musculoskeletal Ultrasound (RMSK). He is a member of the University of California, San Diego Department of Orthopedics voluntary faculty and serves as Medical Director for Personalized Stem Cells, Inc.
Stephen Keane – Chief Business Officer
Mr. Keane is a seasoned life sciences executive with an extensive track record in business development and financial transactions for emerging biopharmaceutical companies. He has experience as CBO, COO, and CEO of several Venture Capital funded companies, including officer roles in publicly traded companies. Keane has raised over $420 million in equity capital in the last two decades and has helped generate more than $450 million in non-dilutive partner revenues to fund drug discovery programs. He was responsible for negotiating multiple acquisitions, alliances including licenses, distributions agreements, technology acquisitions, and research agreements with large pharmaceutical companies and government agencies. His more than 25-year track record with successful biotechnology companies demonstrates his ability to navigate the drug development pathway and raise adequate capital for development and successful exits for our investors.